Methods for using tetanus toxin for beneficial purposes in animals (mammals)
OwnerIra Sandersinventor
Life of this patent
Estimating the term…
Abstract
Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.
Claims30
A method of administering a therapeutically effective amount of tetanus toxin to a selected site, having target neurons whose activity is reversibly affectable thereby, of an animal in need of modulation of activity of said neurons,
- comprising the initial steps, prior to said administration, of
- a) determining the level of antibodies to tetanus toxin present in the blood plasma of said animal,
- b) immunizing the animal where the level of antibodies to tetanus toxin is below 0.1 IU/ml and,
- c) administering a therapeutically effective amount of tetanus toxin to a selected site,
- whereby the neurotoxin reversibly modulates the activity of the target neurons.
A method comprising administering at a selected site in an animal, a therapeutically and modulatorily effective amount of tetanus toxin,
- comprising the initial steps, prior to said administration, of
- a) determining the level of antibodies to tetanus toxin present in the blood plasma of said animal and
- b) immunizing the animal where the level of tetanus toxin is below 0.1 IU/ml
- whereby the cellular activity of said animal at said site is modulated wherein said cellular activity includes release of a cellular component comprising hormones, growth factors, inflammatory modulators from nerves or immune cells and blood cells, cholinergic secretions, mucus secretions from respiratory, digestive or urinary glands.
A pharmaceutical formulation in dosage form for modulating a cellular activity of cells of an animal, comprising a therapeutically effective amount of tetanus toxin in a pharmaceutically acceptable carrier wherein the dosage comprises from about 0.001 units to about 5000 units of tetanus toxin.
A method of preventing the transmission of pain sensation in an animal from a selected site on said animal to the central nervous system comprising
- a) determining the level of antibodies to tetanus toxin present in the blood plasma of said animal and
- b) immunizing said animal where the level of tetanus toxin is below 0.1 IU/ml and
- c) administering to a selected site in said animal, tetanus toxin in a therapeutically effective amount sufficient to decrease or reversibly inhibit the release of inflammatory neurotransmitters or neuropeptides associated with the pain whereby transmission of pain sensation from the selected site to the central nervous system is prevented.
A method of preventing the transmission of pain sensation in an animal from a selected site on said animal to the central nervous system comprising
- a) determining the level of antibodies to tetanus toxin present in the blood plasma of said animal and
- b) immunizing said animal where the level of tetanus toxin is below 0.1 IU/ml and
- c) administering to a selected site in said animal a therapeutically effective amount of tetanus toxin sufficient to decrease the function of sensory neurons, the release or binding of inflammatory neurotransmitters or neuropeptides associated with the pain whereby transmission of pain sensation from the selected site is prevented.
Dependencies are inferred from the claim text.